Spyre Therapeutics, Inc.
SYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636282
In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.
Holders of 5% or more of SYRE
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Spyre Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 13D/A | 9.99%9.67M shares | 0.00 ppfrom 9.99% | Oct 17, 20253 filings | Jun 23, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.60%3.96M shares | – | Jul 16, 20251 filing | Jul 16, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
33 Schedule 13D and 13G filings on Spyre Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20265:22 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 4.90%4.32M shares | −0.10 ppfrom 5.00%Below 5% | Jun 30, 2026 | SEC |
| Aug 14, 20268:10 AM ET | RTW Investments, LPand 1 other | 13G/A | 4.80%4.25M shares | −1.40 ppfrom 6.20%Below 5% | Jun 30, 2026 | SEC |
| Jun 23, 20269:45 PM ET | Fairmount Funds Management LLCand 3 others | 13D/A | 9.99%9.67M shares | 0.00 ppfrom 9.99% | Jun 23, 2026 | SEC |
| Apr 22, 20264:00 PM ET | Perceptive Advisors LLCand 2 others | 13G | 5.00%4.32M shares | +0.60 ppfrom 4.40% | Apr 15, 2026 | SEC |
| Apr 20, 20266:00 PM ET | Fairmount Funds Management LLCand 3 others | 13D/A | 9.99%9.02M shares | 0.00 ppfrom 9.99% | Apr 16, 2026 | SEC |
| Mar 27, 20261:17 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −5.08 ppfrom 5.08%Below 5% | Mar 13, 2026 | SEC |
| Feb 17, 20264:15 PM ET | Tang Capital Management LLCand 5 others | 13G/A | 2.40%1.89M shares | −2.90 ppfrom 5.30%Below 5% | Dec 31, 2025 | SEC |
| Oct 17, 20255:00 PM ET | Fairmount Funds Management LLCand 3 others | 13D/A | 9.99%8.11M shares | – | Oct 15, 2025 | SEC |
| Jul 29, 20252:40 PM ET | Vanguard Group Inc | 13G | 5.08%3.07M shares | New | Jun 30, 2025 | SEC |
| Jul 16, 20257:02 PM ET | BlackRock, Inc. | 13G/A | 6.60%3.96M shares | – | Jun 30, 2025 | SEC |
| May 1, 20254:15 PM ET | Tang Capital Management LLCand 5 others | 13G | 5.30%3.20M shares | New | Apr 24, 2025 | SEC |
| Feb 14, 20256:06 PM ET | Venrock Healthcare Capital Partners III, L.P.and 6 others | 13G/A | 4.60%2.69M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 20254:15 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 4.40%2.57M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 20259:00 AM ET | RTW Investments, LPand 1 other | 13G/A | 6.20%3.62M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 2022 | BCLS II Equity Opportunities, LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Nantahala Capital Management, LLC | 13GOld format | – | – | – | SEC |
| Feb 14, 2022 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | OrbiMed Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Pictet Asset Management SA | 13GOld format | – | – | – | SEC |
| Feb 10, 2022 | Baker Bros. Advisors LP | 13D/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Adage Capital Partners GP, L.L.C. | 13G/AOld format | – | – | – | SEC |
| Dec 16, 2021 | Suvretta Capital Management, LLC | 13GOld format | – | New | – | SEC |
| Mar 19, 2021 | Baker Bros. Advisors LP | 13D/AOld format | – | – | – | SEC |
| Mar 5, 2021 | Baker Bros. Advisors LP | 13DOld format | – | – | – | SEC |
| Feb 16, 2021 | Baker Bros. Advisors LP | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Nantahala Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Lilly Ventures Fund I LLC | 13GOld format | – | New | – | SEC |
| Feb 12, 2021 | OrbiMed Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2021 | Adage Capital Partners GP, L.L.C. | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2021 | Pictet Asset Management SA | 13GOld format | – | New | – | SEC |
| Feb 10, 2021 | LV Management Group, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 2, 20212:56 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Spyre Therapeutics, Inc. shares.
No Form 144 notices for Spyre Therapeutics, Inc. are on file.